Speakers

Mohamed Abou-El-Enein

Head / Clinical Development Platform, Berlin-Brandenburger Centrum für Regenerative Therapien;
Berlin, Deutschland

Mohamed Abou-El-Enein
Mohamed Abou-El-Enein

Profile

Dr. Mohamed Abou-El-Enein has been the head of the clinical development platform at Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité University Hospital since January 2015. The platform is responsible for transforming the research findings of the scientists into clinical applications. He serves as a Teaching Assistant in clinical research at Harvard T.H. Chan School of Public Health and Instructor in Translational Medicine and Regulatory Science at the Berlin-Brandenburg School for Regenerative Therapies (BSRT). Dr. Abou-El-Enein earned his medical degree from Mansoura Faculty of Medicine and has specialized training in Health Care Quality Management at the American University in Cairo (AUC). He received a master’s degree in Pharmaceutical Sciences and Biotechnologies from Strasbourg University, a Clinical Research Certificate from Harvard Medical School and a Doctoral Degree in Economics Research for Cellular Therapies, summa cum laude, from Charité University Hospital. His primary research interests focus on the development and clinical translation of cell and gene therapies where he has succeeded to bring numerous advanced therapies into early phase clinical trials.

Jeffrey Bluestone

Global Head / UCSF School of Medicine; San Francisco, Vereinigte Staaten

Jeffrey Bluestone
Jeffrey Bluestone

Profile

Jeffrey A. Bluestone, PhD, is the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Director of the Hormone Research Institute at the University of California San Francisco (UCSF). Dr. Bluestone is one of the leading immunologists in the field of T-cell activation, co-stimulation, and immune tolerance research that has led to the development of multiple pro-tolerogenic immunotherapies including: CTLA4Ig (the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation), a novel anti-human CD3 antibody being developed to treat Type 1 Diabetes (T1D), and the first CTLA-4 antagonist drugs approved for the treatment of metastatic melanoma. His recent research has focused on the critical role of regulatory T cells (Tregs) in autoimmune diseases such as T1D and Multiple Sclerosis, which has been exploited as a cell-based therapy to treat T1D and organ transplantation. Dr. Bluestone is an academic leader on a national and international scale. He was the founder and first Director of the Immune Tolerance Network (ITN), the largest NIH-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity, and asthma/allergy; Executive Vice Chancellor and Provost at the University of California San Francisco and the former Director of the UCSF Diabetes Center. Finally, Dr. Bluestone has authored more than 400 peer-reviewed publications and has received numerous awards for his work including election to the American Academy of Arts and Sciences, the National Academy of Medicine and the recipient of both Juvenile Diabetes Research Foundation’s Gerold & Kayla Grodsky Basic Science Award and the Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award.

Ulrich Dirnagl

Direktor / Experimentelle Neurologie, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Charité - Universitätsmedizin; Berlin, Deutschland

Ulrich Dirnagl
Ulrich Dirnagl

Profile

The research of Ulrich Dirnagl is focused on stroke, cerebral blood flow regulation, and brain imaging. In preclinical models as well as clinical trials he and his coworkers and collaborators explore mechanisms by which brain ischemia leads to cell death, and develops novel methods to intercept mechanisms of damage in acute brain damage, as well as to foster regeneration and repair of the lesions. He is particulary interested in how the brain protects itself (‘endogenous neuroprotection’), and how the brain interacts with other systems of the body after it has been injured. Closely linked to his interest in stroke pathophysiology is his interest in the coupling of regional blood flow to neuronal acitivity, the mechanism underlying functional brain imaging with MR and PET. Beyond imaging structure and function of the CNS he and his team are developing, validating and using techniques that allow the non-invasive imaging of brain biochemistry and molecular signaling. To this end they use optical, MR, and nuclear medicine approaches in mouse and man. To improve the predictiveness of preclinical translational research he is actively promoting the introduction of quality standards for experimental design and reporting, as well as international collaboration in large, phase III-type preclinical trials. At the Charité Universitätsmedizin Berlin Ulrich Dirnagl serves as Director of the Department of Experimental Neurology, Chief Executive Director of the Center for Stroke Research Berlin, Clinical program coordinator of the Excellence Cluter NeuroCure and the Berlin partner site of the German Center for Neurodegenerative Diseases (DZNE), as well as Program Director of the International Graduate Program Medical Neuroscience.

Georg N. Duda

Stellv. Direktor / BCRT & Direktor / Julius-Wolff Institut für Biomechanik und Muskuloskeletale Regeneration, Charité - Universitätsmedizin; Berlin, Deutschland

Georg N. Duda
Georg N. Duda

Profile

Georg Duda is an engineer and one of the three founding directors of the BCRT. Since 2008, he is also Director of the Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration at the Charité – Universitätsmedizin Berlin. Georg Duda and his team are working on the development of implants for joint replacement and fracture repair. More recently, he has expanded his research portfolio to include studies on the understanding of cellular aging and mechanotransduction as well as on inflammation as key element of the regenerative cascade in bone and muscle healing.

David W. Grainger

Department of Pharmaceutics and Bioengineering, University of Utah; Salt Lake City, Vereinigte Staaten

David W. Grainger
David W. Grainger

Profile

David Grainger is Distinguished Professor and Chair of the Department of Pharmaceutics and Pharmaceutical Chemistry and also member of the Department of Bioengineering at the University of Utah. His research is focused on diverse aspects of materials in medicine, including new diagnostic devices, medical device infections, drug delivery systems, and physiological interactions with nanotechnology in vivo.

Steven Kern

Deputy Director / Quantitative Sciences, Bill & Melinda Gates Foundation; San Francisco, United States

Steven Kern
Steven Kern

Profile

Steven E. Kern, PhD is Deputy Director of Quantitative Sciences at the Bill and Melinda Gates Foundation. The Quantitative Sciences group is focused on quantitative analysis to support program strategies for therapeutic projects that the foundation funds.
Prior to this, he was Global Head of Pharmacology Modeling at Novartis Pharma AG based in Basel Switzerland where he lead a team focused on providing model based drug development support to therapeutics in many disease conditions across all stages of drug development. He joined Novartis in 2010 from the University of Utah in Salt Lake City, Utah where he was Associate Professor of Pharmaceutics, Anesthesiology, and Bioengineering, and served as co-investigator for their NIH funded Pediatric Pharmacology Research Unit. He has designed, conducted, and served as a principal investigator for clinical pharmacology studies in adults and children that spanned the population from preterm infants to elderly adults.

Hans-Gustaf Ljunggren

Dekan / Karolinska Institutet; Stockholm, Schweden

Hans-Gustaf Ljunggren
Hans-Gustaf Ljunggren

Profile

Professor Ljunggren earned his medical and doctoral degrees at Karolinska Institutet and did his post doc at MIT, Cambridge, MA. In 2001, he was appointed Professor of Infection Medicine. The same year, he became Director of the Center for Infectious Medicine (CIM), a Strategic Research Center within infection medicine at Karolinska Institutet. He has authored >250 articles within the fields of immunology, infectious diseases and cancer. His work has been cited >17.500 times, and he has an h-index of 65 (Web of Science).
Immune reactions mediated by NK cells have been a long-standing research focus of Hans-Gustaf Ljunggren. Starting off from simple model systems, studying NK cells in the mouse at a time when little was known about their molecular specificity and function, he and his collaborators has taken this field towards a detailed understanding of their molecular specificity and function. In recent years, he has gone on to explore the same cells in healthy humans and in several human disease contexts. His research group is now also using NK cells in therapeutic settings in the context of malignant diseases of hematopoietic origin.
Professor Ljunggren has been member of the organizing or scientific committees of numerous international conferences. He has had multiple national and international assignments, involving external research evaluations and participation in international advisory boards. He has been the member of the editorial board of several leading international journals within the field of immunology. Since 2008, he is a member of the Nobel Assembly at Karolinska Institutet, which awards the Nobel Prize in Physiology or Medicine.

Glenn D. Prestwich

Presidential Professor / Medicinal Chemistry & Presidential Special Assistant / Faculty Entrepreneurism, University of Utah; Salt Lake City, Vereinigte Staaten

Glenn D. Prestwich
Glenn D. Prestwich

Profile

Glenn D. Prestwich is Presidential Professor of Medicinal Chemistry and Presidential Special Assistant for Faculty Entrepreneurism at the University of Utah. He created and directs the Entrepreneurial Faculty Scholars program at Utah. His research includes phospholipids in cell signaling, synthetic matrices for regenerative medicine, and anti-inflammatory glycosaminoglycans. He co-founded nine companies, including Echelon Biosciences, Glycosan BioSystems, Sentrx Animal Care, GlycoMira Therapeutics, Metallosensors, and Deuteria Agrochemicals. In 2013, he was inducted as a Fellow of the National Academy of Inventors. Other honors include the Utah Governor’s Medal for Science and Technology for 2006, the 2008 Volwiler Research Award of the American Association of Colleges of Pharmacy, the 2010 University of Utah Distinguished Scholarly and Creative Research Award, and the 2014 U of Utah Distinguished Innovation and Impact Award. During 38 years as a faculty member, he has over 650 publications and patents (H-index 82) and has trained over 125 postgraduate scientists. He is also a pilot, a first tenor of the Utah Symphony Chorus, an advocate for chamber music.

Ronenn Roubenoff

Head / Global Translational Medicine, Musculoskeletal Diseases, Novartis Institutes for Biomedical Research; Basel, Schweiz

Ronenn Roubenoff
Ronenn Roubenoff

Profile

Dr. Roubenoff received his MD from Northwestern University, and trained in Internal Medicine and Rheumatology at the Johns Hopkins Hospital, where he was Chief Resident in Medicine. He completed concurrent fellowships in Rheumatology and in Clinical Epidemiology at Johns Hopkins, receiving a Master of Health Science degree. He then trained in Nutrition at Tufts University with Irwin Rosenberg, MD, and in Immunology with Charles Dinarello, MD. He was Chief of the Nutrition, Exercise Physiology, and Sarcopenia (NEPS) Laboratory from 1997 to 2002, and Director of Human Studies from 2001 to 2002, both at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. He is currently Adjunct Professor of Medicine and Nutrition at Tufts. Dr. Roubenoff moved to the biotech/pharma industry in 2002, as Senior Director of Molecular Medicine at Millennium Pharmaceuticals in Cambridge, MA, where he directed research on biomarkers and personalized medicine. In From 2007 to 2009, he was Sr. Director, Immunology Research and Development, at Biogen Idec, where he led the Translational Medicine and Early Development efforts for the Immunology group. In September, 2009, Dr. Roubenoff was appointed Global Head of Musculoskeletal Translational Medicine at Novartis Institutes for Biomedical Research, heading early development for muscle wasting, tendon healing, cartilage repair, and other musculoskeletal disorders.

Andre Terzic

Director / Center for Regenerative Medicine, Mayo Clinic; Rochester, United States

Andre Terzic
Andre Terzic

Profile

Andre Terzic, M.D., Ph.D., has pioneered regenerative medicine at Mayo Clinic. He has authored more than 450 publications, advancing diagnostic and therapeutic strategies for heart failure. His works include team-science efforts in the discovery of genes for dilated cardiomyopathy and atrial fibrillation. He led efforts in the development of next-generation regenerative solutions, including first-in-class products for heart repair. His scientific manuscripts have been cited more than 10,000 times.
Dr. Terzic is Michael S. and Mary Sue Shannon Director, Mayo Clinic Center for Regenerative Medicine, and Marriott Family Professor in Cardiovascular Diseases Research. He is professor of medicine and pharmacology; chair, Discovery-Translation Advisory Board; director, Marriott Heart Disease Research Program; director, National Institutes of Health Cardiovasology Program; and serves on the board of directors, Mayo Collaborative Services.

Hans-Dieter Volk

Direktor / BCRT & Direktor / Institut für Medizinische Immunologie Charité – Universitätsmedizin; Berlin, Deutschland

Hans-Dieter Volk
Hans-Dieter Volk

Profile

Hans-Dieter Volk has been director of the BCRT since its establishment in 2006. In addition, he is head of the Institute of Medical Immunology at the Charité – Universitätsmedizin Berlin since 1994, and the Department of Immunology of the Labor Berlin-Charité Vivantes GmbH since 2011. His translational research work focuses on the development of biomarkers, transplantation immunology, the immunopathogenesis of virus infections of the herpes group of viruses, and the role of inhibitory cytokines and regulatory T cells.